Excessive Daytime Sleepiness Pipeline 2026: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Excessive Daytime Sleepiness pipeline constitutes 10+ key companies continuously working towards developing 12+ Excessive Daytime Sleepiness treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Excessive Daytime Sleepiness Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Excessive Daytime Sleepiness Market.

The Excessive Daytime Sleepiness Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Excessive Daytime Sleepiness Pipeline Report: https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Excessive Daytime Sleepiness treatment therapies with a considerable amount of success over the years. Excessive Daytime Sleepiness Key players such as - Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences, NLS Pharma, XWPharma, Balance Therapeutics, Takeda Pharmaceuticals, Benevolent AI Bio, Avadel Pharmaceuticals, and others, are developing therapies for the Excessive Daytime Sleepiness treatment
• Excessive Daytime Sleepiness Emerging therapies such as - FT218, THN102, SUVN-G3031, Quilience, XW10172, TAK-994, BEN-2001, AXS-12 (Reboxetine), Xywav (JZP-258) for EDS in IH, Wakix (Pitolisant) for EDS in OSA, and others are expected to have a significant impact on the Excessive Daytime Sleepiness market in the coming years.
• In January 2025, Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), and other conditions driven by dysregulated aldosterone, has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application. This approval allows the company to conduct a Phase 2 clinical trial to assess the effects of lorundrostat in treating patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension.
• In November 2024, Axsome Therapeutics announced that its investigational narcolepsy treatment, AXS-12 (reboxetine), has met the primary endpoint in a Phase III trial. In the ENCORE trial (NCT05059223), the norepinephrine reuptake inhibitor and cortical dopamine modulator reduced the frequency of cataplexy attacks by 72% at one month and 82% at six months.
• In September 2024, Alkermes plc (Nasdaq: ALKS) has announced its plans to present clinical data from its Phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at the European Sleep Research Society's (ESRS) 27th Congress, Sleep Europe 2024, set to take place from September 24-27, 2024, in Seville, Spain. ALKS 2680 is the company's novel, investigational oral selective orexin 2 receptor (OX2R) agonist, being developed as a once-daily treatment for narcolepsy, a chronic neurological disorder marked by excessive daytime sleepiness.
• In June 2024, Harmony Biosciences (Nasdaq: HRMY) shared data from its Phase 2 signal detection study, indicating that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with myotonic dystrophy type 1 (DM1).

Excessive Daytime Sleepiness Overview
Excessive Daytime Sleepiness (EDS) is a condition characterized by an overwhelming and persistent need for sleep during the day. Individuals with EDS may feel excessively tired and have difficulty staying awake or alert, even after adequate or prolonged nighttime sleep. This condition can significantly impact daily activities, reducing productivity and increasing the risk of accidents.

Get a Free Sample PDF Report to know more about Excessive Daytime Sleepiness Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Excessive Daytime Sleepiness Pipeline Therapeutics Assessment
• Excessive Daytime Sleepiness Assessment by Product Type
• Excessive Daytime Sleepiness By Stage and Product Type
• Excessive Daytime Sleepiness Assessment by Route of Administration
• Excessive Daytime Sleepiness By Stage and Route of Administration
• Excessive Daytime Sleepiness Assessment by Molecule Type
• Excessive Daytime Sleepiness by Stage and Molecule Type

DelveInsight's Excessive Daytime Sleepiness Report covers around 12+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Excessive Daytime Sleepiness Therapeutics Market include:
Key companies developing therapies for Excessive Daytime Sleepiness are - Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, XWPharma, Takeda Pharmaceutical, and others.

Download Sample PDF Report to know more about Excessive Daytime Sleepiness drugs and therapies
https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Excessive Daytime Sleepiness Drugs Under Different Phases of Clinical Development Include:
• FT218: Avadel Pharmaceuticals
• AXS-12: AxsomeTherapeutics
• THN102: Theranexus
• SUVN-G3031: Suven LifeSciences
• Quilience: NLS Pharma
• XW10172: XWPharma
• TAK-994: Takeda

Excessive Daytime Sleepiness Pipeline Analysis:
The Excessive Daytime Sleepiness pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Excessive Daytime Sleepiness with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Excessive Daytime Sleepiness Treatment.
• Excessive Daytime Sleepiness key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Excessive Daytime Sleepiness Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Excessive Daytime Sleepiness market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Excessive Daytime Sleepiness product details are provided in the report. Download the Excessive Daytime Sleepiness pipeline report to learn more about the emerging Excessive Daytime Sleepiness therapies
https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Excessive Daytime Sleepiness Pipeline Market Drivers
• Robust clinical Excessive Daytime Sleepiness pipeline
• Support of the US FDA by granting designations
• Recent launch of Xywav and Ozawade
• Increasing prevalence due to appearance of EDS as a symptom in various disorders

Excessive Daytime Sleepiness Pipeline Market Barriers
• High cost of Excessive Daytime Sleepiness therapies
• Delay in Excessive Daytime Sleepiness diagnosis
• A limited number of participants
• Lack of practical measurement tools in diagnosis

Scope of Excessive Daytime Sleepiness Pipeline Drug Insight
• Coverage: Global
• Key Excessive Daytime Sleepiness Companies: Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences, NLS Pharma, XWPharma, Balance Therapeutics, Takeda Pharmaceuticals, Benevolent AI Bio, Avadel Pharmaceuticals, and others
• Key Excessive Daytime Sleepiness Therapies: FT218, THN102, SUVN-G3031, Quilience, XW10172, TAK-994, BEN-2001, AXS-12 (Reboxetine), Xywav (JZP-258) for EDS in IH, Wakix (Pitolisant) for EDS in OSA, and others
• Excessive Daytime Sleepiness Therapeutic Assessment: Excessive Daytime Sleepiness current marketed and Excessive Daytime Sleepiness emerging therapies
• Excessive Daytime Sleepiness Market Dynamics: Excessive Daytime Sleepiness market drivers and Excessive Daytime Sleepiness market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.